To access the full Data Trackers, click here for the M&A deals and here for VC deals.
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?
Medtech Money Flow: Weekly M&A And VC Deals, Jan. 1-7
In this new weekly feature, Medtech Insight presents a roundup of the previous week's M&A deals and venture financing rounds recorded in our M&A and VC Deal Trackers. This edition presents the transactions announced between Jan. 1-7, 2018.
More from Deals
• By
Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.
• By
Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.
• By
Tempus expects its $81.25m acquisition of Paige AI to accelerate building the largest oncology foundation model. With its third deal this year, Tempus expands capabilities across genomics, pathology, and clinical trials.
• By
Terumo will acquire OrganOx for about $1.5bn, adding the only FDA-cleared liver normothermic perfusion device to its portfolio. Analysts don’t expect the buyout to have a significant impact on competition, but the deal marks a strategic shift for Terumo into transplant medicine.
More from Business
• By
After divesting bone healing products in mid-year, Highridge Medical doubled down on its spine capabilities with a triple purchase of technologies from Accelus, bringing access to “Adaptive Geometry.” CEO Rebecca Whitney explained Highridge’s strategy.
• By
Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.
• By
Abbott’s Navitor TAVR system is now CE-marked for low to intermediate risk patients, based on positive data from the Vintage trial. The EACTS guidelines for TAVR lowered the recommended age for patients with severe aortic stenosis to 70 years and older, which opens up treatment for younger patients.